Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
This is a phase II trial to explore the efficacy and safety of weekly utidelone in HER2-negative inoperable locally advanced or metastatic breast cancer.
Breast Neoplasms|Locally Advanced or Metastatic Breast Cancer
DRUG: utidelone
Progression free survival (PFS), PFS is defined as the duration from enrollment to the first radiologically confirmed progressive disease (PD) (RECIST 1.1 criteria) or death due to any cause., Estimated 12 months
Objective response rate (ORR), The proportion of patients with a best response of CR or PR, according to RECIST 1.1 criteria, Estimated 12 months|Overall Survival (OS), From enrollment to death (for any reason), Estimated 24 months|Duration of Response (DOR), The first evaluation of CR or PR to progression or death (for any reason), Estimated 12 months|Overall summary of adverse events following intravenous administration of utidelone (safety analysis set), Incidence of treatment-emergent adverse events based the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0\[ Time Frame: 1 years\] Observe and record incidence of adverse events and severe adverse events associated with utidelone treatment, assessed by investigators according to CTCAE version 5.0., Estimated 12 months
This is a phase II trial to explore the efficacy and safety of weekly utidelone in HER2-negative inoperable locally advanced or metastatic breast cancer.